vs
AMREP CORP.（AXR）与CUMBERLAND PHARMACEUTICALS INC（CPIX）财务数据对比。点击上方公司名可切换其他公司
AMREP CORP.的季度营收约是CUMBERLAND PHARMACEUTICALS INC的1.1倍（$14.6M vs $13.7M），AMREP CORP.净利率更高（21.6% vs -10.3%，领先31.9%），AMREP CORP.同比增速更快（93.8% vs 31.1%），AMREP CORP.自由现金流更多（$5.4M vs $3.0K），过去两年CUMBERLAND PHARMACEUTICALS INC的营收复合增速更高（26.9% vs -13.6%）
AMREP是一家总部位于美国新泽西州普林斯顿的企业，核心业务涵盖房地产与媒体服务领域。公司前身为美国地产石油公司，于1961年正式成立，在相关行业拥有六十余年的发展运营历史。
坎伯兰制药是一家专科制药企业，专注于开发、生产和商业化品牌处方药物，核心产品覆盖急症护理、胃肠病、疼痛管理及罕见病治疗领域，主要运营市场为美国，为相关医护人员与患者提供服务。
AXR vs CPIX — 直观对比
营收规模更大
AXR
是对方的1.1倍
$13.7M
营收增速更快
AXR
高出62.7%
31.1%
净利率更高
AXR
高出31.9%
-10.3%
自由现金流更多
AXR
多$5.4M
$3.0K
两年增速更快
CPIX
近两年复合增速
-13.6%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $14.6M | $13.7M |
| 净利润 | $3.1M | $-1.4M |
| 毛利率 | — | 83.6% |
| 营业利润率 | 20.6% | -10.0% |
| 净利率 | 21.6% | -10.3% |
| 营收同比 | 93.8% | 31.1% |
| 净利润同比 | 338.9% | 25.8% |
| 每股收益（稀释后） | $0.58 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXRCPIX
| Q1 26 | $14.6M | — | ||
| Q4 25 | $9.4M | $13.7M | ||
| Q3 25 | $17.9M | $8.3M | ||
| Q2 25 | $11.2M | $10.8M | ||
| Q1 25 | $7.5M | $11.7M | ||
| Q4 24 | $11.9M | $10.4M | ||
| Q3 24 | $19.1M | $9.1M | ||
| Q2 24 | $19.5M | $9.8M |
净利润AXRCPIX
| Q1 26 | $3.1M | — | ||
| Q4 25 | $1.2M | $-1.4M | ||
| Q3 25 | $4.7M | $-1.9M | ||
| Q2 25 | $3.9M | $-740.7K | ||
| Q1 25 | $717.0K | $1.3M | ||
| Q4 24 | $4.0M | $-1.9M | ||
| Q3 24 | $4.1M | $-1.5M | ||
| Q2 24 | $4.1M | $-1.1M |
毛利率AXRCPIX
| Q1 26 | — | — | ||
| Q4 25 | — | 83.6% | ||
| Q3 25 | — | 88.1% | ||
| Q2 25 | — | 81.4% | ||
| Q1 25 | — | 87.8% | ||
| Q4 24 | — | 81.1% | ||
| Q3 24 | — | 85.4% | ||
| Q2 24 | — | 82.6% |
营业利润率AXRCPIX
| Q1 26 | 20.6% | — | ||
| Q4 25 | 11.9% | -10.0% | ||
| Q3 25 | 34.4% | -23.7% | ||
| Q2 25 | 31.7% | -6.9% | ||
| Q1 25 | 5.7% | 11.0% | ||
| Q4 24 | 26.4% | -17.7% | ||
| Q3 24 | 26.1% | -18.6% | ||
| Q2 24 | 23.9% | -10.4% |
净利率AXRCPIX
| Q1 26 | 21.6% | — | ||
| Q4 25 | 12.8% | -10.3% | ||
| Q3 25 | 26.3% | -23.4% | ||
| Q2 25 | 34.8% | -6.8% | ||
| Q1 25 | 9.5% | 10.7% | ||
| Q4 24 | 33.9% | -18.2% | ||
| Q3 24 | 21.3% | -17.0% | ||
| Q2 24 | 21.2% | -11.0% |
每股收益（稀释后）AXRCPIX
| Q1 26 | $0.58 | — | ||
| Q4 25 | $0.22 | $-0.09 | ||
| Q3 25 | $0.87 | $-0.13 | ||
| Q2 25 | $0.73 | $-0.05 | ||
| Q1 25 | $0.13 | $0.08 | ||
| Q4 24 | $0.75 | $-0.13 | ||
| Q3 24 | $0.76 | $-0.11 | ||
| Q2 24 | $0.77 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $50.0M | $11.4M |
| 总债务越低越好 | $21.0K | — |
| 股东权益账面价值 | $139.4M | $24.9M |
| 总资产 | $143.9M | $76.8M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资AXRCPIX
| Q1 26 | $50.0M | — | ||
| Q4 25 | $44.6M | $11.4M | ||
| Q3 25 | $48.9M | $15.2M | ||
| Q2 25 | $39.5M | $16.1M | ||
| Q1 25 | $36.9M | $15.1M | ||
| Q4 24 | $40.1M | $18.0M | ||
| Q3 24 | $40.4M | $17.5M | ||
| Q2 24 | $29.7M | $17.3M |
总债务AXRCPIX
| Q1 26 | $21.0K | — | ||
| Q4 25 | $23.0K | — | ||
| Q3 25 | $25.0K | — | ||
| Q2 25 | $26.0K | — | ||
| Q1 25 | $29.0K | — | ||
| Q4 24 | $32.0K | — | ||
| Q3 24 | $34.0K | — | ||
| Q2 24 | $35.0K | — |
股东权益AXRCPIX
| Q1 26 | $139.4M | — | ||
| Q4 25 | $136.0M | $24.9M | ||
| Q3 25 | $134.7M | $26.1M | ||
| Q2 25 | $130.0M | $28.0M | ||
| Q1 25 | $126.0M | $28.7M | ||
| Q4 24 | $125.1M | $22.9M | ||
| Q3 24 | $122.2M | $24.8M | ||
| Q2 24 | $118.0M | $26.3M |
总资产AXRCPIX
| Q1 26 | $143.9M | — | ||
| Q4 25 | $140.1M | $76.8M | ||
| Q3 25 | $140.7M | $65.9M | ||
| Q2 25 | $133.8M | $67.9M | ||
| Q1 25 | $128.9M | $69.9M | ||
| Q4 24 | $129.1M | $75.6M | ||
| Q3 24 | $127.0M | $76.7M | ||
| Q2 24 | $122.8M | $78.5M |
负债/权益比AXRCPIX
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.4M | $3.0K |
| 自由现金流经营现金流 - 资本支出 | $5.4M | $3.0K |
| 自由现金流率自由现金流/营收 | 37.0% | 0.0% |
| 资本支出强度资本支出/营收 | 0.1% | 0.0% |
| 现金转化率经营现金流/净利润 | 1.72× | — |
| 过去12个月自由现金流最近4个季度 | $20.2M | $4.8M |
8季度趋势，按日历期对齐
经营现金流AXRCPIX
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | $3.0K | ||
| Q3 25 | $9.5M | $187.2K | ||
| Q2 25 | $10.2M | $843.8K | ||
| Q1 25 | $-3.2M | $3.9M | ||
| Q4 24 | $-182.0K | $1.9M | ||
| Q3 24 | $10.7M | $475.5K | ||
| Q2 24 | $10.7M | $-855.7K |
自由现金流AXRCPIX
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | $3.0K | ||
| Q3 25 | $9.5M | $163.4K | ||
| Q2 25 | $9.7M | $817.3K | ||
| Q1 25 | $-3.3M | $3.9M | ||
| Q4 24 | $-268.0K | $1.9M | ||
| Q3 24 | $10.7M | $460.1K | ||
| Q2 24 | $10.3M | $-862.8K |
自由现金流率AXRCPIX
| Q1 26 | 37.0% | — | ||
| Q4 25 | -45.9% | 0.0% | ||
| Q3 25 | 53.2% | 2.0% | ||
| Q2 25 | 86.4% | 7.5% | ||
| Q1 25 | -43.4% | 32.9% | ||
| Q4 24 | -2.3% | 18.2% | ||
| Q3 24 | 55.8% | 5.1% | ||
| Q2 24 | 52.5% | -8.8% |
资本支出强度AXRCPIX
| Q1 26 | 0.1% | — | ||
| Q4 25 | 0.6% | 0.0% | ||
| Q3 25 | 0.1% | 0.3% | ||
| Q2 25 | 5.2% | 0.2% | ||
| Q1 25 | 0.3% | 0.4% | ||
| Q4 24 | 0.7% | 0.0% | ||
| Q3 24 | 0.2% | 0.2% | ||
| Q2 24 | 2.3% | 0.1% |
现金转化率AXRCPIX
| Q1 26 | 1.72× | — | ||
| Q4 25 | -3.54× | — | ||
| Q3 25 | 2.03× | — | ||
| Q2 25 | 2.63× | — | ||
| Q1 25 | -4.51× | 3.10× | ||
| Q4 24 | -0.05× | — | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 2.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
